Reducing Re-Excision Rates: A Clinical Imperative

Re-excision surgeries for breast cancer are a significant concern for both patients and healthcare systems. They impose additional physical and psychological stress on patients, prolong recovery times, and increase healthcare costs. The primary reason for re-excisions is the presence of positive margins – cancerous cells found at the edge of the removed tissue – which are typically identified days after the initial surgery. clearcut directly addresses this challenge by providing immediate, intraoperative margin assessment. By allowing surgeons to verify clear margins before the patient leaves the operating room, our system dramatically reduces the need for subsequent procedures. This not only improves patient experience but also optimizes hospital resource allocation and surgical scheduling. The clinical benefits are clear: faster recovery, less anxiety, and a more streamlined treatment pathway for breast cancer patients.

The impact of reducing re-excision rates extends beyond individual patient care. It contributes to a more efficient and sustainable healthcare model for oncology. With clearcut, hospitals can enhance their surgical performance metrics and demonstrate a commitment to adopting cutting-edge technologies that improve patient safety and outcomes. The system's ability to deliver precise, real-time information empowers surgical teams to achieve the 'one-and-done' surgery goal more consistently. This paradigm shift from delayed pathology results to immediate feedback fundamentally changes the surgical workflow, making it more proactive and patient-focused. Embracing technologies that prevent re-excisions is not just a clinical advancement; it's an ethical responsibility to minimize patient burden and maximize treatment effectiveness in the fight against breast cancer.